Comparative Study
. 2000 Oct;85(10 Suppl):69-71; discussion 71-2.
Regimens of factor VIII administration--continuous infusion vs. bolus
Affiliations
- PMID: 11187875
Item in Clipboard
Comparative Study
Regimens of factor VIII administration--continuous infusion vs. bolus
Haematologica.
2000 Oct.
Abstract
The Malmö protocol for immune tolerance induction uses intermittent injections of factor VIII/IX together with intravenous IgG and cyclophosphamide. In order to increase the production of antigen-antibody complexes, and also to improve cost-efficacy, we applied continuous infusion instead of intermittent injection in 5 high-responders (3 hemophilia A and 2 hemophilia B). All treatment attempts failed. However, we conclude that continuous infusion may play a role in immune tolerance induction, and the treatment failures in our study could probably be explained by the fact that the patients were partially selected to be resistant cases.
Similar articles
-
Immune tolerance induction and the treatment of hemophilia. Malmö protocol update.Haematologica. 2000 Oct;85(10 Suppl):48-50; discussion 50-1. Haematologica. 2000. PMID: 11187871
-
Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.Prog Clin Biol Res. 1990;324:69-78. Prog Clin Biol Res. 1990. PMID: 2106694 No abstract available.
-
Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.N Engl J Med. 1988 Apr 14;318(15):947-50. doi: 10.1056/NEJM198804143181503. N Engl J Med. 1988. PMID: 3127711
-
Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.Thromb Haemost. 1999 Aug;82(2):531-9. Thromb Haemost. 1999. PMID: 10605747 Review. No abstract available.
-
The management of hemophilia patients with inhibitors.Transfus Med Rev. 1992 Oct;6(4):285-93. doi: 10.1016/s0887-7963(92)70185-0. Transfus Med Rev. 1992. PMID: 1421831 Review. No abstract available.